MARKET

IMVT

IMVT

Immunovant Inc
NASDAQ
23.98
-1.38
-5.44%
After Hours: 23.80 -0.18 -0.75% 16:54 03/27 EDT
OPEN
25.26
PREV CLOSE
25.36
HIGH
25.56
LOW
23.95
VOLUME
1.13M
TURNOVER
--
52 WEEK HIGH
29.25
52 WEEK LOW
12.72
MARKET CAP
4.88B
P/E (TTM)
-8.9384
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMVT last week (0316-0320)?
Weekly Report · 4d ago
Top Immunovant Executive Quietly Cashes Out in Notable Insider Stock Move
TipRanks · 6d ago
Bernstein initiates Immunovant with a Market Perform, $28 price target
TipRanks · 03/20 12:50
IMMUNOVANT INC <IMVT.O>: BERNSTEIN INITIATES COVERAGE WITH MARKET-PERFORM RATING; TARGET PRICE $28
Reuters · 03/20 10:18
U.S. RESEARCH ROUNDUP-Air Products, Chevron, FedEx
Reuters · 03/20 06:50
Immunovant initiated with a Market Perform at Bernstein
TipRanks · 03/19 20:22
Tracking Baker Brothers Portfolio - Q4 2025 Update
Seeking Alpha · 03/18 00:54
Weekly Report: what happened at IMVT last week (0309-0313)?
Weekly Report · 03/16 09:21
More
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

Webull offers Immunovant Inc stock information, including NASDAQ: IMVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMVT stock methods without spending real money on the virtual paper trading platform.